Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL, USA.
Br J Pharmacol. 2013 Aug;169(8):1862-78. doi: 10.1111/bph.12247.
Activation of α7 nicotinic acetylcholine receptors (nAChRs) can be neuroprotective. However, endogenous choline and ACh have not been regarded as potent neuroprotective agents because physiological levels of choline/ACh do not produce neuroprotective levels of α7 activation. This limitation may be overcome by the use of type-II positive allosteric modulators (PAMs-II) of α7 nAChRs, such as 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)-urea (PNU-120596). This proof-of-concept study presents a novel neuroprotective paradigm that converts endogenous choline/ACh into potent neuroprotective agents in cerebral ischaemia by inhibiting α7 nAChR desensitization using PNU-120596.
An electrophysiological ex vivo cell injury assay (to quantify the susceptibility of hippocampal neurons to acute injury by complete oxygen and glucose deprivation; COGD) and an in vivo middle cerebral artery occlusion model of ischaemia were used in rats.
Choline (20-200 μM) in the presence, but not absence of 1 μM PNU-120596 significantly delayed anoxic depolarization/injury of hippocampal CA1 pyramidal neurons, but not CA1 stratum radiatum interneurons, subjected to COGD in acute hippocampal slices and these effects were blocked by 20 nM methyllycaconitine, a selective α7 antagonist, thus, activation of α7 nAChRs was required. PNU-120596 alone was ineffective ex vivo. In in vivo experiments, both pre- and post-ischaemia treatments with PNU-120596 (30 mg·kg(-1) , s.c. and 1 mg·kg(-1) , i.v., respectively) significantly reduced the cortical/subcortical infarct volume caused by transient focal cerebral ischaemia. PNU-120596 (1 mg·kg(-1) , i.v., 30 min post-ischaemia) remained neuroprotective in rats subjected to a choline-deficient diet for 14 days prior to experiments.
PNU-120596 and possibly other PAMs-II significantly improved neuronal survival in cerebral ischaemia by augmenting neuroprotective effects of endogenous choline/ACh.
激活α7 烟碱型乙酰胆碱受体(nAChRs)具有神经保护作用。然而,由于内源性胆碱和 ACh 不能产生神经保护作用,因此它们不能被视为有效的神经保护剂。这种局限性可以通过使用α7 nAChR 的 II 型正变构调节剂(PAMs-II)来克服,例如 1-(5-氯-2,4-二甲氧基苯基)-3-(5-甲基异恶唑-3-基)-脲(PNU-120596)。这项概念验证研究提出了一种新的神经保护范式,通过使用 PNU-120596 抑制α7 nAChR 脱敏,将内源性胆碱/ACh 转化为脑缺血中的有效神经保护剂。
在大鼠中使用体外细胞损伤电生理学测定(通过完全缺氧和葡萄糖剥夺来量化海马神经元对急性损伤的敏感性;COGD)和大脑中动脉闭塞模型的缺血。
在急性海马切片中,当存在但不存在 1 μM PNU-120596 时,20-200 μM 胆碱可显著延迟缺氧去极化/海马 CA1 锥体神经元损伤,但不延迟 CA1 辐射层中间神经元损伤,这些作用被选择性α7 拮抗剂 20 nM 甲基-6-氯乙酰基-10,11-二氢-5H-二苯并[b,f]氮杂卓-6-甲酰胺阻断,因此需要激活α7 nAChR。单独使用 PNU-120596 在体外无效。在体内实验中,预先和缺血后用 PNU-120596(分别为 30 mg·kg(-1) , 皮下注射和 1 mg·kg(-1) , 静脉注射)治疗均可显著减少短暂性局灶性脑缺血引起的皮质/皮质下梗死体积。在实验前 14 天接受胆碱缺乏饮食的大鼠中,PNU-120596(1 mg·kg(-1) , 静脉注射,缺血后 30 分钟)仍然具有神经保护作用。
PNU-120596 和可能的其他 PAMs-II 通过增强内源性胆碱/ACh 的神经保护作用,显著改善了脑缺血中的神经元存活。